# Prime Medicine, Inc. > Clarifo company profile — qualitative business description generated from > the company's filings. Financial statements, charts and ratios are > available on Clarifo (https://www.clarifo.com/en/companies/Prime Medicine, Inc.). ## Overview Prime Medicine, Inc. is a U.S.-based biotechnology company developing Prime Editing, a gene-editing platform designed to make precise DNA changes for genetic diseases and other disorders. The company’s pipeline includes wholly owned in vivo programs, an ex vivo cell-therapy collaboration, and early discovery efforts, with operations centered in Cambridge, Massachusetts. ## Products & services • Prime Editing gene-editing platform • In vivo genetic medicine programs • PM359 for chronic granulomatous disease • Wilson Disease and AATD programs • Cystic Fibrosis discovery program • Ex vivo T-cell engineering collaboration with BMS - **Prime Editing platform** (0%) — Core gene-editing technology used to create precise DNA edits across multiple therapeutic programs. - **Wholly owned in vivo programs** (45%) — Liver-directed genetic medicine programs targeting Wilson Disease, AATD, and related indications. - **Clinical-stage PM359 program** (20%) — Program for chronic granulomatous disease intended to validate Prime Editing in humans. - **Collaborative ex vivo programs** (20%) — Partnered cell-engineering work with BMS applying Prime Editing to T-cell therapies. - **Discovery and enabling technologies** (15%) — Early-stage research, LNP delivery, manufacturing, and IND-enabling development work. - Prime Editing gene-editing platform - In vivo genetic medicine programs - PM359 for chronic granulomatous disease - Wilson Disease and AATD programs - Cystic Fibrosis discovery program - Ex vivo T-cell engineering collaboration with BMS ## Customers Prime Medicine does not sell commercial products; its current customers are collaboration partners and, in the future, regulators and healthcare providers if programs reach approval. Revenue to date has come from research collaboration and license agreements, while the underlying therapeutic end markets are patients with serious genetic diseases and immune/oncology disorders. - **Strategic collaboration partners** (primary) — Pharmaceutical and biotech partners that pay for access to Prime Editing capabilities, shared development, or licensed programs. - **Rare disease patients** (primary) — Patients with defined genetic disorders such as Wilson Disease, AATD, and CGD who would use approved therapies if developed. - **Oncology and immunology partners** (secondary) — Partners and future treatment centers involved in ex vivo T-cell engineering and related cell therapy applications. - **Research and translational ecosystem** (secondary) — Academic, foundation, and disease-advocacy collaborators that support discovery, data generation, and program advancement. - Pharma partners that license or co-develop Prime Editing programs - BMS for ex vivo T-cell engineering collaboration - Potential future patients with rare genetic liver diseases - Potential future patients with chronic granulomatous disease - Potential future clinical and regulatory stakeholders for approvals ## Geography Prime Medicine is headquartered in Cambridge, Massachusetts and operates as a U.S.-based development-stage biotech company. Its business is primarily organized around U.S. research, clinical, and regulatory activities, while collaborations and future development work may extend into Europe and other markets through partners and trial sites. - Headquartered in Cambridge, Massachusetts - U.S. clinical and regulatory focus for lead programs - Potential future trial and partner activity in Europe - Collaborations may broaden geographic reach without owned sales force - No commercial manufacturing footprint disclosed ## Strategy The company’s strategy is to advance Prime Editing from platform validation into clinical development, starting with liver-directed programs and PM359. It also uses partnerships, such as BMS, to expand the platform into ex vivo applications while preserving internal focus on its highest-priority in vivo pipeline. - **Advance liver-directed in vivo programs** (short-term) — Wilson Disease and AATD are core franchise opportunities and near-term clinical catalysts. - **Validate Prime Editing in humans** (short-term) — Clinical proof-of-concept supports platform credibility and future partnering. - **Expand through collaborations** (medium-term) — Partnerships can add capabilities and funding without overextending internal resources. - **Build development infrastructure** (medium-term) — Clinical-stage execution requires manufacturing, quality, and regulatory readiness. - Advance in vivo liver programs toward IND/CTA filings - Use PM359 as a human validation program for Prime Editing - Leverage partnerships to extend platform reach - Build manufacturing, quality, and regulatory infrastructure - Expand Prime Editing into new disease areas over time ## Risks Prime Medicine faces the typical risks of a pre-commercial biotech: clinical failure, regulatory delays, and dependence on external capital and partners. Its platform also depends on complex manufacturing, intellectual property protection, and third-party supply chains, including some China-linked inputs that could be disrupted by geopolitical or policy changes. - **Clinical development failure** [critical] — Prime Editing programs are still in preclinical or early clinical stages and may not translate into approved therapies. - **Regulatory delay or non-approval** [high] — Gene-editing therapies require extensive FDA/EMA review and may need additional data or longer follow-up. - **Financing and going-concern pressure** [high] — The company has no product sales and depends on external funding to sustain development. - **Partner concentration and collaboration execution** [high] — A meaningful portion of value creation depends on successful third-party collaborations and license arrangements. - **Supply chain and geopolitical exposure** [medium] — Preclinical and clinical development may rely on China-based suppliers or service providers that could be restricted. - Clinical programs may fail to show safety or efficacy - Regulatory timelines can slip or require additional data - Additional capital may be needed before commercialization - Collaborations may not deliver expected value or funding - Third-party and China-linked supply chains can be disrupted - Expanded access use can create safety and publicity risks ## Accounting Revenue is recognized under contract accounting for collaboration and license arrangements, so timing depends on the pattern of performance obligations rather than product shipments. The company also relies heavily on estimates for stock-based compensation, accrued R&D, and contingent collaboration obligations, which can materially affect reported expenses and period-to-period comparability. - **ASC 606 collaboration revenue** — Can shift revenue between periods without changing cash receipts - **Stock-based compensation valuation** — Can materially affect operating expenses and equity compensation cost - **Accrued research and development** — Can change reported R&D expense and liabilities - **Contingent collaboration milestones** — Creates off-balance-sheet style economic obligations and expense uncertainty - Collaboration revenue recognized over performance periods - R&D service estimates affect timing of revenue recognition - Stock-based compensation depends on option valuation inputs - Accrued R&D and prepaid expenses require management estimates - Milestone and royalty obligations are contingent and uncertain --- *Last updated: 2026-04-29T04:49:27.736193+00:00*